Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Organon & Co. (OGN) vs Scilex Holding Company (SCLX)

Organon & Co. and Scilex Holding Company are both Drug Manufacturers General companies. Organon & Co. is the larger, with a market value of $3.6B against $34.8M — 103.6× the size. Scilex Holding Company has negative trailing earnings, so its P/E is not meaningful; Organon & Co. trades at 17.4×. Organon & Co. grew revenue faster over the last twelve months: −2.45% against −28.6%. Organon & Co. has the higher net margin (3.41% vs −1,418.5%) and the higher return on invested capital (6.11% vs 0.00%). Across the 18 metrics below, Organon & Co. leads on 12 and Scilex Holding Company on 6.

Valuation

Metric OGN SCLX Drug Manufacturers General median
P/E 17.38 n/m 24.72
P/S 0.59 1.07 3.35
P/B 3.58 n/m 5.00
Price to free cash flow 7.77 n/m 17.68
EV/EBITDA 7.82 n/m 13.91
EV/Sales 1.80 3.63 3.95
Earnings yield 5.75% (1,016.36%) 2.92%
Free cash flow yield 12.87% (52.87%) 4.42%

Profitability

Metric OGN SCLX Drug Manufacturers General median
Gross margin 52.68% 55.50% 72.77%
Operating margin 13.45% (1,136.40%) 18.90%
Net margin 3.41% (1,418.45%) 8.27%
Free cash flow margin 7.57% (56.37%) 17.25%
Return on equity 24.04% 160.27% 6.97%
Return on assets 1.57% (265.83%) 2.76%
Return on invested capital 6.11% 0.00% 6.30%

Growth

Metric OGN SCLX Drug Manufacturers General median
Revenue growth (TTM) (2.45%) (28.55%) 6.79%
EPS growth (last fiscal year) (78.38%) (408.32%) —
Revenue growth, 5-year CAGR (0.99%) (0.69%) 3.98%
Net income growth, 5-year CAGR (38.70%) 0.00% 0.42%

Health

Metric OGN SCLX Drug Manufacturers General median
Debt to equity 8.50 (0.26) 0.63
Current ratio 1.95 0.07 1.32
Net debt to EBITDA 5.62 (0.27) 1.15

Dividend

Metric OGN SCLX Drug Manufacturers General median
Dividend yield 6.88% — 3.57%
Payout ratio 0.38 0.00 0.53

Size

Metric OGN SCLX Drug Manufacturers General median
Market cap 3.60b 34.75m 125.91b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack